BibTex RIS Cite

Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi

Year 2015, Volume: 15 Issue: 3, 107 - 110, 01.07.2015

Cemile Pehlivanoğlu Ilmay Bilge Bağdagül Aksu Alev Yılmaz Zeynep Yürük Yıldırım Yasin Yılmaz Işın Kılıçaslan Sevinç Emre

https://doi.org/10.5222/j.child.2015.107

Abstract

Sistemik Lupus Eritematozus, heterojen otoinflamatuar bir hastalıktır. Patofizyolojisinde genetik nedenlerin yanında çevresel multifaktöryel etkenler suçlanmıştır. B hücrelerinin aşırı aktivasyonunun lupus patofizyolojisin- de önemli rol oynadığı gösterilmiştir. Çocuklarda tedavi- sinde steroidler ve immunsupresif ajanlar kullanılmakta- dır. Rituksimab, B lenfositlerin CD20 antijenlerine karşı geliştirilen bir biyolojik ajandır. B hücrelerine bağlı oto- inflamatuvar hastalıklarda etkin olduğu gösterilmiştir. Bu makalede, ciddi komplikasyonları olan ve diğer immun- supresif tedavilere yanıt vermeyen sistemik lupus eritema- tozus tanılı çocuk vakasında rituksimab tedavisi deneyimi paylaşılacaktır

Keywords

Sistemik Lupus Eritematozus rituksimab immunsupresif ajanlar

References

  • mir S, keskinoğlu a. Çocukluk çağı lupus nefriti izle- minde anti-dsDNA düzeyi. Ege Tıp Dergisi 2003;42(1):19-24.
  • makay B, ünsal E. Jüvenil sistemik lupus eritemato- zus. Klinik Gelişim 2006;19(1):24-33.
  • Livingston B, Bonner a, Pope J. Differences in clini- cal manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011;20(13): 1345-55. http://dx.doi.org/10.1177/0961203311416694
  • Vachvanichsanong P, mcneil E. Pediatric lupus neph- ritis: more options, more chances? Lupus 2013;22(6): 545-53. http://dx.doi.org/10.1177/0961203313485490
  • rovin Bh, Furie r, Latinis k, Looney rJ, Fervenza FC, Sanchez-Guerrero J et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64(4):1215-26. http://dx.doi.org/10.1002/art.34359
  • Pinto LF, Velásquez CJ, Prieto C, mestra L, Forero E, márquez Jd. Rituximab induces a rapid and susta- ined remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus 2011;20(11):1219-26. http://dx.doi.org/10.1177/0961203311409273
  • davies rJ, Sangle Sr, Jordan nP, aslam L, Lewis mJ, Wedgwood r et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013; 22(6):574-82. http://dx.doi.org/10.1177/0961203313483376
  • Trachana m, koutsonikoli a, Farmaki E, Printza n, Tzimouli V, Papachristou F. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythe- matosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 2013;33(3):809-13. http://dx.doi.org/10.1007/s00296-011-2239-6
  • Willems m, haddad E, niaudet P, koné-Paut I, Bensman a, Cochat P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148(5):623-27. http://dx.doi.org/10.1016/j.jpeds.2006.01.041
  • Lehman TJ, Singh C, ramanathan a, alperin r, adams a, Barinstein L et al. Prolonged improvement of childhood onset systemic lupus erythematosus follo- wing systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 2014; 12:3. http://dx.doi.org/10.1186/1546-0096-12-3

Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus

Year 2015, Volume: 15 Issue: 3, 107 - 110, 01.07.2015

Cemile Pehlivanoğlu Ilmay Bilge Bağdagül Aksu Alev Yılmaz Zeynep Yürük Yıldırım Yasin Yılmaz Işın Kılıçaslan Sevinç Emre

https://doi.org/10.5222/j.child.2015.107

Abstract

Systemic Lupus Erythematosus SLE is a heterogeneous autoinflammatory disease. Genetic and environmental multi- factorial agents have been implicated in its pathophysiology. Hyperactivation of B cells has been demonstrated to play a central role in SLE pathophysiology. Steroids and immuno- suppressive agents are administered in the treatment of child- ren. Rituximab is a biologic agent developed against CD20 antigens of B cells. It has been shown that rituximab is effec- tive in B cell-dependent autoinflammatory diseases. In this paper, we will share our experience about rituximab treatment of a pediatric case with the diagnosis of lupus erythematosus with severe complications and unresponsive to other immuno- suppressive therapies

Keywords

Systemic Lupus Erythematosus SLE rituximab immunosuppressive agents

References

  • mir S, keskinoğlu a. Çocukluk çağı lupus nefriti izle- minde anti-dsDNA düzeyi. Ege Tıp Dergisi 2003;42(1):19-24.
  • makay B, ünsal E. Jüvenil sistemik lupus eritemato- zus. Klinik Gelişim 2006;19(1):24-33.
  • Livingston B, Bonner a, Pope J. Differences in clini- cal manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011;20(13): 1345-55. http://dx.doi.org/10.1177/0961203311416694
  • Vachvanichsanong P, mcneil E. Pediatric lupus neph- ritis: more options, more chances? Lupus 2013;22(6): 545-53. http://dx.doi.org/10.1177/0961203313485490
  • rovin Bh, Furie r, Latinis k, Looney rJ, Fervenza FC, Sanchez-Guerrero J et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64(4):1215-26. http://dx.doi.org/10.1002/art.34359
  • Pinto LF, Velásquez CJ, Prieto C, mestra L, Forero E, márquez Jd. Rituximab induces a rapid and susta- ined remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus 2011;20(11):1219-26. http://dx.doi.org/10.1177/0961203311409273
  • davies rJ, Sangle Sr, Jordan nP, aslam L, Lewis mJ, Wedgwood r et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013; 22(6):574-82. http://dx.doi.org/10.1177/0961203313483376
  • Trachana m, koutsonikoli a, Farmaki E, Printza n, Tzimouli V, Papachristou F. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythe- matosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 2013;33(3):809-13. http://dx.doi.org/10.1007/s00296-011-2239-6
  • Willems m, haddad E, niaudet P, koné-Paut I, Bensman a, Cochat P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148(5):623-27. http://dx.doi.org/10.1016/j.jpeds.2006.01.041
  • Lehman TJ, Singh C, ramanathan a, alperin r, adams a, Barinstein L et al. Prolonged improvement of childhood onset systemic lupus erythematosus follo- wing systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 2014; 12:3. http://dx.doi.org/10.1186/1546-0096-12-3
There are 10 citations in total.

Details

Primary Language Turkish
Journal Section Research Articles
Authors

Cemile Pehlivanoğlu This is me

Ilmay Bilge This is me

Bağdagül Aksu This is me

Alev Yılmaz This is me

Zeynep Yürük Yıldırım This is me

Yasin Yılmaz This is me

Işın Kılıçaslan This is me

Sevinç Emre This is me

Publication Date July 1, 2015
Published in Issue Year 2015 Volume: 15 Issue: 3

Cite

APA Pehlivanoğlu, C., Bilge, I., Aksu, B., Yılmaz, A., et al. (2015). Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi. Çocuk Dergisi, 15(3), 107-110. https://doi.org/10.5222/j.child.2015.107
AMA Pehlivanoğlu C, Bilge I, Aksu B, Yılmaz A, Yürük Yıldırım Z, Yılmaz Y, Kılıçaslan I, Emre S. Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi. Çocuk Dergisi. July 2015;15(3):107-110. doi:10.5222/j.child.2015.107
Chicago Pehlivanoğlu, Cemile, Ilmay Bilge, Bağdagül Aksu, Alev Yılmaz, Zeynep Yürük Yıldırım, Yasin Yılmaz, Işın Kılıçaslan, and Sevinç Emre. “Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi”. Çocuk Dergisi 15, no. 3 (July 2015): 107-10. https://doi.org/10.5222/j.child.2015.107.
EndNote Pehlivanoğlu C, Bilge I, Aksu B, Yılmaz A, Yürük Yıldırım Z, Yılmaz Y, Kılıçaslan I, Emre S (July 1, 2015) Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi. Çocuk Dergisi 15 3 107–110.
IEEE C. Pehlivanoğlu, I. Bilge, B. Aksu, A. Yılmaz, Z. Yürük Yıldırım, Y. Yılmaz, I. Kılıçaslan, and S. Emre, “Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi”, Çocuk Dergisi, vol. 15, no. 3, pp. 107–110, 2015, doi: 10.5222/j.child.2015.107.
ISNAD Pehlivanoğlu, Cemile et al. “Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi”. Çocuk Dergisi 15/3 (July 2015), 107-110. https://doi.org/10.5222/j.child.2015.107.
JAMA Pehlivanoğlu C, Bilge I, Aksu B, Yılmaz A, Yürük Yıldırım Z, Yılmaz Y, Kılıçaslan I, Emre S. Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi. Çocuk Dergisi. 2015;15:107–110.
MLA Pehlivanoğlu, Cemile et al. “Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi”. Çocuk Dergisi, vol. 15, no. 3, 2015, pp. 107-10, doi:10.5222/j.child.2015.107.
Vancouver Pehlivanoğlu C, Bilge I, Aksu B, Yılmaz A, Yürük Yıldırım Z, Yılmaz Y, Kılıçaslan I, Emre S. Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi. Çocuk Dergisi. 2015;15(3):107-10.